Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2010
11/10/2010CN101104637B Cecropin and its generation bacterial strain and use
11/10/2010CN101091789B Application of ocean collagen peptide in preparing medicine or foodstuff for adjusting immunity
11/10/2010CN101068556B Pilose antler nano-products containing enriched insulin-like growth factor and producing method thereof
11/10/2010CN101015680B Use of F-Glucoside peptide in preparing medicine for treating tumour
11/09/2010US7829693 Compositions and methods for inhibiting expression of a target gene
11/09/2010US7829688 nucleic acid encoding peptide that inhibits the interaction of CaV2.2 with Mint1-PDZ1, a glutathione S transferase fusion protein; neurotransmitter-release angonists of CaV2.2, the pore-forming subunit of N-type of voltage-dependent calcium channels; antinocciceptive agents
11/09/2010US7829684 in high yields, with native conformation, and/or in soluble form include solubilizing in non-ionic or zwitterionic detergents; comprises polynucleotide encoding a multiple-membrane-spanning CD20 polypeptide
11/09/2010US7829679 Mucin-type glycoprotein and use thereof
11/09/2010US7829676 Whitefly ecdysone receptor antibody
11/09/2010US7829675 TWEAK receptor
11/09/2010US7829672 Modulation of sodium channels in dorsal root ganglia
11/09/2010US7829671 human endonuclease protein, MED1 (methyl-CpG binding endonuclease 1); drug screening; genetic or cancer screening assays
11/09/2010US7829670 Filamin A interacting protein 1 for use in directed destruction of actin binding protein filamin-1; treating neurodegenerative disorders
11/09/2010US7829669 Catalytically active recombinant memapsin and methods of use thereof
11/09/2010US7829668 Analyzing amino acid sequences of cytokines and immunotoxins, then deleting selected tripeptides, to form mutant toxins used as vaccines
11/09/2010US7829666 toxins belonging to the same structural class of K+ channel-acting short-chain scorpion toxins (less than 40 amino acid residues) that are cross-linked by four disulfide bridges; modulating a K+ channel in a cell; nerve disorder therapy
11/09/2010US7829664 encoding a human pro-insulin leader, a glucagon-like peptide-1 (GLP-1), and a furin cleavable site between the human pro-insulin leader sequence and the GLP-1; Type II diabetes, hyperglycemia; reducing weight in a subject by implanting into the subject an immunoisolatory device
11/09/2010US7829663 F11 receptor (F11R) antagonists as therapeutic agents
11/09/2010US7829662 BH3 interacting domain death agonist for use in prevention ans treatment of apoptosis associated disorders
11/09/2010US7829596 administering to the patient an effective amount of a xanthine oxidase inhibitor ( allopurinol, 7,8-dihydroneopterin, 5,6,7,8-tetrahydrobiopterin, leukopterin, xanthopterin, neopterin etc.) to reduce sympathetic nervous system activity and/or improving cardiovascular reflex status for treating cachexia
11/09/2010US7829573 Therapeutic combinations of antihypertensive and antiangiogenics agents
11/09/2010US7829564 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
11/09/2010US7829549 Methods for treating bleeding disorders using sulfated polysaccharides
11/09/2010US7829541 Heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium
11/09/2010US7829540 Amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium; side effect reduction; side effect reduction
11/09/2010US7829539 Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
11/09/2010US7829538 Heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium
11/09/2010US7829537 drug biological conjugates used in the diagnosis, prophylaxis, or treatment of nervous system disorders or lysosomal storage diseases; drug delivery; blood brain barriers
11/09/2010US7829536 administering to a patient with lymphedema a therapeutically effective amount of a vascular endothelial growth factor D (VEGF-D) protein at the site of edema, that binds and stimulates wild-type VEGFR-3; genetic disorders; screening
11/09/2010US7829535 for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors.
11/09/2010US7829534 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
11/09/2010US7829533 Cyclosporin analog formulations
11/09/2010US7829532 Method of treating a nerve-related vision disorder in a non-diabetic subject
11/09/2010US7829531 monoclonal antibody conjugated with peptide drug such as dolastatin derivative
11/09/2010US7829530 Inhibiting dipeptidylpeptidase proteolysis of glucagon-like peptide 1 by conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV; treating Type II diabetes but not sufficient to suppress the immune system of the animal
11/09/2010US7829529 Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
11/09/2010US7829527 administering to a subject having cerebral vasospasm an effective amount for treating cerebral vasospasm of a R-type voltage-dependent calcium channel inhibitor SNX-482 ( a polypeptide from spider; toxin from the venom of the tarantula Hysterocrates gigas)
11/09/2010US7829526 DNA encoding peptide, an antibody against the peptide; cardioinhibitory, hypotensive agent; peptide as an active ingredient; marker protein, peptide tag
11/09/2010US7829525 a surface active substance, in particular a non-ionic detergent (tenside), and a mixture of at least two amino acids, are either Glu and Gln or Asp and Asn for stabilization of protein agents in pharmaceuticals
11/09/2010US7829524 nucleic acid constructs, vectors, and host cells; detergents; transgenic plants; animal feeds
11/09/2010US7829523 Method for stabilizing polypeptides lacking methionine
11/09/2010US7829330 Stresscopins and their uses
11/09/2010US7829329 Adenoviral vectors for treating disease
11/09/2010US7829307 Multimeric protein with linker having sequence ProValSerGlyProArg; [Gly2]hGLP-2 is produced from a multimeric precursor; genetic engineering and expression; biodrugs
11/09/2010US7829297 selecting therapy for a human subject having a solid epithelial tumor that overexpresses ErbB2 comprising determining whether the tumor expresses p95ErbB2; reversible dual tyrosine kinase inhibitor of both ErbB2 and epidermal growth factor receptor
11/09/2010US7829126 Infant formulas containing docosahexaenoic acid and lutein
11/09/2010US7829124 administering an effective amount of an aqueous or alcohol extract of Phyllanthus to a mammal infected with the YMDD hepatitis B virus mutant strain resistant; inhibiting viral gene expression in a mammal infected with a hepatitis B virus
11/09/2010US7829123 Process
11/09/2010US7829117 reaction product of polystyrene bound mesna (mercaptoethanesulfonic acid, sodium salt) and a sulfur-containing amino acid, preferably cysteine; chemical intermediates; anticarcinogenic agent; side effect reduction; heteroconjugate
11/09/2010US7829112 Forming two drug permeable polymeric segments, exposing to preferential drug, connecting segments, delivering drug treatment; for use in treatment of menopausal symptoms and benign ovarian secretory disorder; contraceptive
11/09/2010US7829109 Catheter injectable depot compositions and uses thereof
11/09/2010US7829097 Use of HMGB1 for protection against ischemia reperfusion injury
11/09/2010US7829092 Recombinant anti-VLA4 antibody molecules
11/09/2010US7829091 Therapy targeting FLT4 (VEGER-3) expressed in blood vessels
11/09/2010US7829082 Catheter composition and uses thereof
11/09/2010US7829081 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
11/09/2010US7829080 stably retaining reduced coenzyme Q10 by protection against oxidation while maintaining high safety, during processing; useful as a food, nutritional product, nutritional supplement, animal drug, drink, feed, cosmetic, pharmaceutical product; dosage form
11/09/2010US7829078 Drug delivery; sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery; increasing the hematocrit and/or the reticulocyte count in a mammalian subject
11/09/2010US7829077 kit comprising an IFN- alpha selected from IFN- alpha -2a, IFN- alpha -2b, IFN- alpha -5, consensus interferon, purified IFN- alpha , pegylated IFN- alpha and a pharmaceutically acceptable quantity of oncostatin M
11/09/2010US7829076 increase the production of monocytic cells or moncyte cell progenitors by culturing bone marrow or blood cells with a polypeptide for use in treatment and prevention of viral hepatitis diseases; N-terminal methionine; rheumatoid arthritis, multiple sclerosis, myasthenia gravis, systemic lupus, leukemia
11/09/2010US7829075 Method for expanding hematopoietic cells using cytokine zalpha11 ligand
11/09/2010US7829074 Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG
11/09/2010US7829072 Hypoallergens
11/09/2010US7829067 Method and composition for treating oral bacteria and inflammation
11/09/2010US7829064 antigen binding molecules conjugated to lipids, polymer carriers, micelles, nanoparticles or mixtures and effectors, used for therapy of diagnosis
11/09/2010US7827982 Biodrug delivery via thermal inkjet method for transmucosal delivery; peptides and proteins such as insulin, growth hormone, antibodies, interferons, cytokines
11/09/2010CA2412899C Medicinal preparations for treating sex hormone-dependent diseases
11/09/2010CA2412493C Purging of cells using viruses
11/09/2010CA2407659C Growth hormone secretagogues
11/09/2010CA2386242C Tumour-specific vector for gene therapy
11/09/2010CA2362794C Inhibitors of separase, method for identifying them and uses
11/09/2010CA2223532C Monkey monoclonal antibodies specific to human b7.1 and/or b7.2 primatized forms, pharmaceutical compositions
11/09/2010CA2208420C Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission
11/09/2010CA2161684C Bioactive and/or targeted dendrimer conjugates
11/09/2010CA2137815C Dna sequences used in the production of recombinant human bssl/cel in transgenic non-human mammals, and the produced bssl/cel used in infant formulas
11/04/2010WO2010127336A1 Modified compstatin with peptide backbone and c-terminal modifications
11/04/2010WO2010127326A1 E6 binding peptides for use in affinity purification
11/04/2010WO2010127301A1 Method of treating allergic conjunctivitis with cyclosporin compositions
11/04/2010WO2010127209A2 Compositions and methods for therapy of macular degeneration
11/04/2010WO2010126833A1 Sustained release formulations of peptidomimetic drugs and uses thereof
11/04/2010WO2010126553A1 Compositions and methods for reducing the likelihood of implantation failure or spontaneous abortion in recipients of assisted reproduction
11/04/2010WO2010126528A1 Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
11/04/2010WO2010126194A1 Autologous and allogenic adipose-derived stromal stem cell composition for treating fistulas
11/04/2010WO2010126180A1 Creatine kinase fusion protein, preparation method thereof, and use thereof
11/04/2010WO2010126169A1 Pharmaceutical composition for preventing vascular disorders which comprises alk1 inhibitor as active ingredient
11/04/2010WO2010126036A1 Combined drug
11/04/2010WO2010125910A1 Collagen peptide composition having good blood transfer properties, and food and drink containing same
11/04/2010WO2010125566A2 Markers for cancer detection
11/04/2010WO2010125475A2 Sustained release formulations
11/04/2010WO2010125192A1 Use of a casein-derived peptide and compositions thereof as antihypertensive
11/04/2010WO2010125148A2 Methods for treating ocular conditions
11/04/2010WO2010124857A1 Intrastriatal botulinum toxin therapy
11/04/2010WO2010124547A1 Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
11/04/2010WO2010124428A1 A stabilizer for preparing freeze-dried vaccine without gelatin and the preparation method of freeze-dried vaccine
11/04/2010WO2010124365A1 Compositions and methods for modulating stem cells and uses thereof
11/04/2010WO2010124361A1 Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
11/04/2010WO2010089768A3 Bortezumib containing pharmaceutical composition
11/04/2010WO2010080769A3 Chemotherapeutic methods and compositions
11/04/2010WO2010080188A3 Epitope targeted anthrax vaccine
11/04/2010WO2010079998A3 Use of hog, ras, and camp signal pathway genes for fungal infection treatment
1 ... 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 ... 3163